Irbesartan Sandoz

Irbesartan, the active ingredient in Irbesartan Sandoz, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for systemic use. It lowers blood pressure and protects kidney function in patients with hypertension and diabetic kidney disease.

GNH USA supplies Irbesartan Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent batch release, comprehensive documentation, and responsive technical support throughout the supply chain.

Irbesartan acts on the renin‑angiotensin system to manage conditions related to high blood pressure and renal protection. - Hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular risk profile. - Diabetic nephropathy: slows progression of kidney damage in type 2 diabetes, reducing proteinuria. - Cardiovascular risk reduction: lowers risk of stroke and heart failure in hypertensive patients with left ventricular hypertrophy.

Irbesartan may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Upper respiratory tract infection

Serious or Rare Side Effects: - Angioedema - Hyperkalemia - Acute renal failure - Hepatic injury

When prescribing Irbesartan, clinicians should observe several precautionary measures to ensure safe use. - Blood pressure monitoring: check baseline and periodic readings to assess efficacy. - Renal function assessment: evaluate serum creatinine and eGFR before initiation and during therapy. - Serum potassium surveillance: monitor for hyperkalemia, especially when combined with potassium‑sparing agents. - Pregnancy contraindication: avoid use in pregnancy due to fetal toxicity (Category D). - Hepatic impairment caution: adjust therapy in patients with moderate to severe liver disease. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Irbesartan can interact with other medicines, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid): - Aliskiren in diabetic patients: concurrent use may increase risk of renal dysfunction, hyperkalemia, and hypotension. - Dual blockade with ACE inhibitors or other ARBs: may cause excessive hypotension, renal impairment, and elevated potassium. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function. - Thiazide diuretics: additive blood pressure lowering; monitor for hypotension. - Lithium: reduced clearance may raise lithium levels; monitor serum concentrations.